Celgene's Phase 3 results with their new psoriasis drug were "good" as they would say . . . I would say 50% improvement is "fair". But, they are Celgene and they will probably get FDA approval. So, I still think the bar is very low for Prurisol . . . if we can clear a statistically significant advantage over Celgene (50%) than we have something! Big licensing agreement would be great and key to completing Kevetrin trials.... will also do wonders for CTIX share price.